Printer Friendly

Viralytics reports publication of pre-clinical research on combination of CAVATAK and chemotherapy in breast cancer.

M2 PHARMA-January 13, 2011-Viralytics reports publication of pre-clinical research on combination of CAVATAK and chemotherapy in breast cancer(C)2011 M2 COMMUNICATIONS

13 January 2011 - Australian oncolytic virus technology company Viralytics Ltd (ASX: VLA) announced today the publication of pre-clinical research data on the anti-cancer activity of its lead oncolytic virus candidate, CAVATAKTM (Coxsackievirus A21) in combination with chemotherapy on human breast cancers both in vitro and in vivo.

The combination studies were undertaken over a number of years by researchers in the School of BioMedical Sciences and Pharmacy at The University of Newcastle.

The peer reviewed article entitled "Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride" has now been published online in advance of print in the international journal Investigational New Drugs. The article describes the enhanced anti-cancer activity of CAVATAKTM administered in combination with doxorubicin hydrochloride (a chemotherapeutic agent) as a new therapeutic regimen for both laboratory cultures of human breast cancer cells and mouse tumours models of human breast cancer. The presented findings highlight the potential of CAVATAKTM to be used in combination with existing chemotherapy, forming new therapeutic regimes in the treatment of human breast cancer.

Doxorubicin hydrochloride is approved by the US Food and Drug Administration (FDA) for use in the treatment of a number of metastatic human cancers including as breast, gastric, small cell lung and ovarian cancers.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 13, 2011
Words:238
Previous Article:Ono and Galapagos' BioFocus ink target discovery deal in autoimmune diseases area.
Next Article:Watson sees at least 25% Y/Y rise in 2010 net revenues.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters